Good morning! 

Plenty to digest today.

Final list:




Sosandar (LON:SOS)

  • Share price: 42p (+5%)
  • No. of shares: 107 million
  • Market cap: £45 million

AGM Statement

This popular share is being watched and commented upon by plenty of analysts and investors. Today's statement is worth recording for the archives:

I am pleased to confirm that the momentum outlined in our Final Results Statement in July continued through the summer months, with significant progress across KPIs and without the need for extended discounted promotional activity. Autumn has begun well with further expansion of the product range and strong trading across all product categories.

Trading is in line with expectations. The company is happy with the PR impact it's making from celebrity promotions and is now getting a 7-day service from its partner Clipper Logistics (LON:CLG).

My view: there are no numbers given so nothing concrete to analyse. We just have the reassurance that KPIs (conversion rate, number of orders, etc.) are making "significant progress".

Sales are forecast this year (ending March 2019) at £3.9 million. In July, Paul suggested a range of £4 million - £5 million was realistic.

It's too early-stage for me, but I wish it well.




Science in Sport (LON:SIS)

  • Share price: 70p (+0.4%)
  • No. of shares: 68 million
  • Market cap: £47 million

Half-year Report

I've collected more than my fair share of useless knowledge about this sports nutrition business over the years. 

The idea is that the company would turn profitable or at least breakeven at some point, and I would be able to nip in and buy the shares when they finally offered a lower-risk investment opportunity.

Today's H1 report wants to be that breakthrough point, but I don't know if I'm convinced.

H1 highlights (and lowlights):

  • revenues +20% to £10 million.
  • operating loss increases to £1.6 million (adjusted EBITDA).
  • excluding USA/Italy/Australia, instead focusing on what SIS calls its "core business", EBITDA…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here